432 research outputs found
Recommended from our members
Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease.
ObjectiveTo understand the safety, putaminal coverage, and enzyme expression of adeno-associated viral vector serotype-2 encoding the complementary DNA for the enzyme, aromatic L-amino acid decarboxylase (VY-AADC01), delivered using novel intraoperative monitoring to optimize delivery.MethodsFifteen subjects (three cohorts of 5) with moderately advanced Parkinson's disease and medically refractory motor fluctuations received VY-AADC01 bilaterally coadministered with gadoteridol to the putamen using intraoperative magnetic resonance imaging (MRI) guidance to visualize the anatomic spread of the infusate and calculate coverage. Cohort 1 received 8.3 × 1011 vg/ml and ≤450 μl per putamen (total dose, ≤7.5 × 1011 vg); cohort 2 received the same concentration (8.3 × 1011 vg/ml) and ≤900 μl per putamen (total dose, ≤1.5 × 1012 vg); and cohort 3 received 2.6 × 1012 vg/ml and ≤900 μl per putamen (total dose, ≤4.7 × 1012 vg). (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography (PET) at baseline and 6 months postprocedure assessed enzyme activity; standard assessments measured clinical outcomes.ResultsMRI-guided administration of ascending VY-AADC01 doses resulted in putaminal coverage of 21% (cohort 1), 34% (cohort 2), and 42% (cohort 3). Cohorts 1, 2, and 3 showed corresponding increases in enzyme activity assessed by PET of 13%, 56%, and 79%, and reductions in antiparkinsonian medication of -15%, -33%, and -42%, respectively, at 6 months. At 12 months, there were dose-related improvements in clinical outcomes, including increases in patient-reported ON-time without troublesome dyskinesia (1.6, 3.3, and 1.5 hours, respectively) and quality of life.InterpretationNovel intraoperative monitoring of administration facilitated targeted delivery of VY-AADC01 in this phase 1 study, which was well tolerated. Increases in enzyme expression and clinical improvements were dose dependent. ClinicalTrials.gov Identifier: NCT01973543 Ann Neurol 2019;85:704-714
COS-Speech: Protocol to develop a core outcome set for dysarthria after stroke for use in clinical practice and research
BACKGROUND: Dysarthria after stroke is when speech intelligibility is impaired, and this occurs in half of all stroke survivors. Dysarthria often leads to social isolation, poor psychological well-being and can prevent return to work and social lives. Currently, a variety of outcome measures are used in clinical research and practice when monitoring recovery for people who have dysarthria. When research studies use different measures, it is impossible to compare results from trials and delays our understanding of effective clinical treatments. The aim of this study is to develop a core outcome set (COS) to agree what aspects of speech recovery should be measured for dysarthria after stroke (COS-Speech) in research and clinical practice. METHODS: The COS-Speech study will include five steps: (1) development of a long list of possible outcome domains of speech that should be measured to guide the survey; (2) recruitment to the COS-Speech study of three key stakeholder groups in the UK and Australia: stroke survivors, communication researchers and speech and language therapists/pathologists; (3) two rounds of the Delphi survey process; (4) a consensus meeting to agree the speech outcomes to be measured and a follow-up consensus meeting to match existing instruments/measures (from parallel systematic review) to the agreed COS-Speech; (5) dissemination of COS-Speech. DISCUSSION: There is currently no COS for dysarthria after stroke for research trials or clinical practice. The findings from this research study will be a minimum COS, for use in all dysarthria research studies and clinical practice looking at post-stroke recovery of speech. These findings will be widely disseminated using professional and patient networks, research and clinical forums as well as using a variety of academic papers, videos, accessible writing such as blogs and links on social media. TRIAL REGISTRATION: COS-Speech is registered with the Core Outcome Measures in Effectiveness Trials (COMET) database, October 2021 https://www.comet-initiative.org/Studies/Details/1959. In addition, “A systematic review of the psychometric properties and clinical utility of instruments measuring dysarthria after stroke” will inform the consensus meeting to match measures to COS-Speech. The protocol for the systematic reviews registered with the International Prospective Register of Systematic Reviews. PROSPERO registration number: CRD42022302998. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06958-7
Recommended from our members
Combatting Substandard and Falsified Medicines: A View from Rwanda
Agnes Binagwaho and colleagues describe Rwanda's experience of pharmacovigilance for malaria and tuberculosis, and call for a global treaty and leadership by the World Health Organization to address the global manufacture and trade in substandard and falsified medicines. Please see later in the article for the Editors' Summar
Striatal dopamine D2/D3 receptor binding in pathological gambling is correlated with mood-related impulsivity
AbstractPathological gambling (PG) is a behavioural addiction associated with elevated impulsivity and suspected dopamine dysregulation. Reduced striatal dopamine D2/D3 receptor availability has been reported in drug addiction, and may constitute a premorbid vulnerability marker for addictive disorders. The aim of the present study was to assess striatal dopamine D2/D3 receptor availability in PG, and its association with trait impulsivity. Males with PG (n=9) and male healthy controls (n=9) underwent [11C]-raclopride positron emission tomography imaging and completed the UPPS-P impulsivity scale. There was no significant difference between groups in striatal dopamine D2/D3 receptor availability, in contrast to previous reports in drug addiction. However, mood-related impulsivity (‘Urgency’) was negatively correlated with [11C]-raclopride binding potentials in the PG group. The absence of a group difference in striatal dopamine binding implies a distinction between behavioural addictions and drug addictions. Nevertheless, our data indicate heterogeneity in dopamine receptor availability in disordered gambling, such that individuals with high mood-related impulsivity may show differential benefits from dopamine-based medications
Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals
Post mortem neuropathology suggests that astrocyte reactivity may play a significant role in neurodegeneration in Alzheimer’s disease. We explored this in vivo using multimodal PET and MRI imaging. Twenty subjects (11 older, cognitively impaired patients and 9 age-matched healthy controls) underwent brain scanning using the novel reactive astrocyte PET tracer (11)C-BU99008, (18)F-FDG and (18)F-florbetaben PET, and T1-weighted MRI. Differences between cognitively impaired patients and healthy controls in regional and voxel-wise levels of astrocyte reactivity, glucose metabolism, grey matter volume and amyloid load were explored, and their relationship to each other was assessed using Biological Parametric Mapping (BPM). Amyloid beta (Aβ)-positive patients showed greater (11)C-BU99008 uptake compared to controls, except in the temporal lobe, whilst further increased (11)C-BU99008 uptake was observed in Mild Cognitive Impairment subjects compared to those with Alzheimer’s disease in the frontal, temporal and cingulate cortices. BPM correlations revealed that regions which showed reduced (11)C-BU99008 uptake in Aβ-positive patients compared to controls, such as the temporal lobe, also showed reduced (18)F-FDG uptake and grey matter volume, although the correlations with (18)F-FDG uptake were not replicated in the ROI analysis. BPM analysis also revealed a regionally-dynamic relationship between astrocyte reactivity and amyloid uptake: increased amyloid load in cortical association areas of the temporal lobe and cingulate cortices was associated with reduced (11)C-BU99008 uptake, whilst increased amyloid uptake in primary motor and sensory areas (in which amyloid deposition occurs later) was associated with increased (11)C-BU99008 uptake. These novel observations add to the hypothesis that while astrocyte reactivity may be triggered by early Aβ-deposition, sustained pro-inflammatory astrocyte reactivity with greater amyloid deposition may lead to astrocyte dystrophy and amyloid-associated neuropathology such as grey matter atrophy and glucose hypometabolism, although the evidence for glucose hypometabolism here is less strong
Recommended from our members
Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model
Background
There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper compares the cost-effectiveness of psilocybin assisted psychotherapy (PAP) with conventional medication, cognitive behavioural therapy (CBT), and the combination of conventional medication and CBT.
Methods
A decision model simulated patient events (response, remission, and relapse) following treatment. Data on probabilities, costs and quality-adjusted life years (QALYs) were derived from previous studies or from best estimates. Expected healthcare and societal costs and QALYs over a 6-month time period were calculated. Sensitivity analyses were used to address uncertainty in parameter estimates.
Results
The expected healthcare cost of PAP varied from £6132 to £7652 depending on the price of psilocybin. This compares to £3528 for conventional medication alone, £4250 for CBT alone, and £4197 for their combination. QALYs were highest for psilocybin (0.310), followed by CBT alone (0.283), conventional medication alone (0.278), and their combination (0.287). Psilocybin was shown to be cost-effective compared to the other therapies when the cost of therapist support was reduced by 50% and the psilocybin price was reduced from its initial value to £400 to £800 per person. From a societal perspective, psilocybin had improved cost-effectiveness compared to a healthcare perspective.
Conclusions
Psilocybin has the potential to be a cost-effective therapy for severe depression. This depends on the level of psychological support that is given to patients receiving psilocybin and the price of the drug itself. Further data on long-term outcomes are required to improve the evidence base
Global access to surgical care: a modelling study
Background More than 2 billion people are unable to receive surgical care based on operating theatre density alone.
The vision of the Lancet Commission on Global Surgery is universal access to safe, aff ordable surgical and anaesthesia
care when needed. We aimed to estimate the number of individuals worldwide without access to surgical services as
defi ned by the Commission’s vision.
Methods We modelled access to surgical services in 196 countries with respect to four dimensions: timeliness,
surgical capacity, safety, and aff ordability. We built a chance tree for each country to model the probability of surgical
access with respect to each dimension, and from this we constructed a statistical model to estimate the proportion of
the population in each country that does not have access to surgical services. We accounted for uncertainty with oneway
sensitivity analyses, multiple imputation for missing data, and probabilistic sensitivity analysis.
Findings At least 4·8 billion people (95% posterior credible interval 4·6–5·0 [67%, 64–70]) of the world’s population
do not have access to surgery. The proportion of the population without access varied widely when stratifi ed by
epidemiological region: greater than 95% of the population in south Asia and central, eastern, and western sub-
Saharan Africa do not have access to care, whereas less than 5% of the population in Australasia, high-income North
America, and western Europe lack access.
Interpretation Most of the world’s population does not have access to surgical care, and access is inequitably
distributed. The near absence of access in many low-income and middle-income countries represents a crisis, and as
the global health community continues to support the advancement of universal health coverage, increasing access to
surgical services will play a central role in ensuring health care for all
Crop Updates 2000 Cereals - part 3
This session covers eighteen papers from different authors:
BARLEY AND OAT AGRONOMY
1. Unicorn barley must meet malting specifications to be a viable option, Roslyn Jettnerand Blakely Paynter, Agriculture Western Australia
2. Optimum oat seed rates, Glenn McDonald, Agriculture Western Australia
3. Production and Quality of export Oaten Hay (1998 and 1989), Pierre Fievez, Pierre Fievez and Associates
FROST
4. Climatology of Frost in Southern Western Australia, Ian Foster, Agriculture Western Australia
5. Flowering calculator, David Tennant, Agriculture Western Australia
6. Some options for managing the risk of frost damage, Wal Anderson, Agriculture Western Australia
PASTURE
7. TIMERITE® Control of redlegged earth mite in south western Australia with a spring spray to pastures, James Ridsdill-Smith and Celia Pavri, CSIRO Entomology, University of Western Australia
8. The pattern of seed softening in subterranean clover in relation to presicted false break risk, Ross Chapman and Senthold Asseng, CSIRO Plant Industry, Centre for Mediterranean Agricultural Research
9. Charano serradella – a viable option for 1:1 cropping, Steve Carr and Brad Nutt IAMA Agri-Services Western Australia and Centre for Legumes in Mediterranean Agriculture, University of Western Australia
10. Alfalfa mosaic virus in alternative annual pasture and forage legumes, Lindrea Latham and Roger Jones, Crop Improvement Institute, Agriculture Western Australia and Centre for Legumes in Mediterranean Agriculture, University of Western Australia
11. Pasture mixture performs better than single-species-based pasture – 1999, Anyou Liu, Clinton Revell and David Ferris, Centre for Cropping Systems, Agriculture Western Australia
12. Better pasture management improves performance of following crops – 1999, Anyou Liu, Clinton Revell and David Ferris, Centre for Cropping Systems, Agriculture Western Australia
13. Lucerne Benefits Crop Production, Roy Latta1, Lisa-Jane Blacklow2, Chris Matthews1 1Agriculture Western Australia 2University of Western Australia
14. Does size count? Determining optimum release number of red apion for biocontrol of doublegee, Tim Woodburn and Paul Yeoh, CSIRO Entomology/CRC Weed Management Systems, Perth
15. Herbicide tolerance of some new cultivars of annual pasture legumes, Clinton Revell and Ian Rose, Centre for Cropping Systems, Agriculture Western Australia
16. Lucerne – crop rotations in the Esperance region, Anita Lyons, Roy Latta and Chris Matthews,Agriculture Western Australia
PRECISION AGRICULTURE
17. Assessing the results of on-farm experiments using yield monitors, Simon Cook and Matthew Adams, CSIRO Land and Water
18. Achiever: A GIS based achievable yield and fertiliser recommendation system for precision agriculture, Robert J. Corner, Matthew L. Adams, Precision Agriculture Research Group CSIRO Land and Wate
- …